| http://www.w3.org/ns/prov#value | - e actions of regulatory bodies, including the FDA and foreign counterparts, (ix) reimbursement and rebate policies of government agencies and private payers, (x) the Company's ability to protect its intellectual property, (xi) the company's ability to successfully divest its interest in Erye, and (xii) matters described under the Risk Factors" in the Company's Annual Report on Form 10-K filed wit
|
